Surgery Partners Inc Stock Price, News & Analysis

Surgery Partners (NASDAQ:SGRY) announced that subsidiary Surgery Center Holdings intends to offer an additional $425.0 million aggregate principal amount of its 7.250% senior unsecured notes due 2032, to be issued as part of the same series as the April 2024 notes.

The Notes will be guaranteed on a senior unsecured basis by each domestic wholly owned subsidiary that guarantees the issuer’s senior secured credit facilities. Net proceeds are intended for general corporate purposes, including possible repayment of outstanding borrowings under the company’s revolving credit facility. The offering will be limited to qualified institutional buyers (Rule 144A) in the U.S. and non-U.S. persons under Regulation S, and the Notes will not be registered under the Securities Act.

Surgery Partners (NASDAQ:SGRY) and Baylor Scott & White Health formed a joint venture announced Dec 08, 2025 to jointly own the 16-bed Physicians Centre Hospital in Bryan, Texas.

The hospital will operate under the Baylor Scott & White name while Surgery Partners will continue day-to-day management. Patients can keep current providers. Services include bariatric, ophthalmologic, oral/maxillofacial, orthopedic, GI, podiatric, spinal, urologic, general, plastic/reconstructive surgery, sports medicine, pain management and radiology.

Surgery Partners (NASDAQ:SGRY) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $821.5 million, up 6.6% YoY; same-facility revenue rose 6.3%. Adjusted EBITDA was $136.4 million, up 6.1% YoY, while net loss attributable was $22.7 million. Year-to-date revenue was $2,423.7 million, up 7.7%, with YTD Adjusted EBITDA of $369.3 million. Liquidity included $203.4 million cash and $405.9 million revolver capacity. Leverage was ~4.2x net debt/EBITDA and 4.6x consolidated debt/Adj EBITDA. Full-year 2025 guidance: $3.275–3.30 billion revenue and $535–540 million Adjusted EBITDA.

Management noted softer-than-expected volume and payor mix and delayed capital deployment as drivers of a prudent fourth-quarter outlook.

Surgery Partners (NASDAQ:SGRY) will release its third quarter 2025 results before the market opens on Monday, November 10, 2025, followed by a conference call at 8:30 a.m. ET.

Live dial-in numbers: 1-877-451-6152 (domestic) and 1-201-389-0879 (international). A replay will be available three hours after the call until November 24, 2025 at 1-844-512-2921 (domestic) and 1-412-317-6671 (international). Passcode for live and replay: 13756022. A simultaneous webcast and replay will be available on the company Investor Relations website at www.surgerypartners.com.

Surgery Partners (NASDAQ:SGRY) reported strong Q2 2025 financial results, with revenue increasing 8.4% to $826.2 million and Adjusted EBITDA growing 9.0% to $129.0 million. Same-facility revenues rose 5.1%, driven by a 3.4% increase in cases and 1.6% growth in revenue per case.

The company reaffirmed its full-year 2025 guidance, projecting revenue between $3.30-3.45 billion and Adjusted EBITDA of $555-565 million. Surgery Partners maintained strong liquidity with $250.1 million in cash and $394.9 million available under its revolving credit facility, while operating cash flow was $81.3 million for Q2 2025.

Surgery Partners (NASDAQ:SGRY), a leading short-stay surgical facility operator, has scheduled its second quarter 2025 earnings release for Tuesday, August 5, 2025, before market open. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results.

Investors can access the call via phone (1-844-826-3033 domestic, 1-412-317-5185 international) or through a simultaneous webcast on the Investor Relations section of Surgery Partners' website. A replay will be available for two weeks until August 19, 2025, using passcode 10201328.

Surgery Partners (NASDAQ:SGRY) announced that discussions with Bain Capital regarding their proposal to acquire remaining outstanding shares have concluded without a deal. The Independent Committee determined that the company's prospects as a public entity exceeded Bain's proposal value. Surgery Partners reaffirmed its 2025 financial guidance, projecting revenues of $3.30-3.45 billion and Adjusted EBITDA of $555-565 million. The company plans to host an Investor Day in H2 2025 to present its growth strategy. Management expressed confidence in the company's positioning in the outpatient surgical care market, citing strong Q1 performance, favorable surgical trends, and a positive regulatory landscape. Bain Capital, while unable to reach agreement terms, remains optimistic about Surgery Partners' business and will continue as long-term investors.

Surgery Partners (NASDAQ:SGRY) reported Q1 2025 results with revenue increasing 8.2% to $776.0 million. Same-facility revenues grew 5.2% with a 6.5% increase in cases, despite a slight decline in revenue per case. The company posted a net loss of $37.7 million but achieved Adjusted EBITDA growth of 6.6% to $103.9 million. Surgery Partners maintained its full-year 2025 guidance, projecting revenues of $3.30-3.45 billion and Adjusted EBITDA of $555-565 million. The company reported strong liquidity with $229.3 million in cash and $388.9 million in credit facility capacity, maintaining a net debt to EBITDA ratio of approximately 4.1x.

Surgery Partners (NASDAQ:SGRY) has scheduled its first quarter 2025 earnings release and conference call. The company will release Q1 2025 results before market open on Monday, May 12, 2025, followed by a conference call at 8:30 a.m. Eastern Time.

Investors can access the live call via phone at 1-877-451-6152 (domestic) or 1-201-389-0879 (international). A replay will be available for two weeks until May 26, 2025, accessible at 1-844-512-2921 (domestic) or 1-412-317-6671 (international) using passcode 13752904.

A simultaneous webcast will be available on the Investor Relations section of Surgery Partners' website at www.surgerypartners.com, where the replay will also be accessible.